Skip to main content
Enter the terms you wish to search for.
Select Search Option
This Site
All WCM Sites
Directory
Menu
Weill Cornell Medicine
Care
Discover
Teach
Beltran Lab
Explore this Website
Home
About Us
Toggle About Us menu options
Contact Us
Job Opportunities
Videos
Affiliations
Research
Lab Team
News
Publications
Weill Cornell Medicine
Care
Discover
Teach
Home
About Us
Affiliations
Research
Lab Team
News
Publications
Home
Publications
Publications
Found 69 results
Author
Title
Type
Year
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
L
Lin D
,
Wyatt AW
,
Xue H
,
Wang Y
,
Dong X
,
Haegert A
,
Wu R
,
Brahmbhatt S
,
Mo F
,
Jong L
et al.
. 2014.
High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development.
.
Cancer Res. 74(4):1272-83.
Lin P-C
,
Chiu Y-L
,
Banerjee S
,
Park K
,
Mosquera JMiguel
,
Giannopoulou E
,
Alves P
,
Tewari AK
,
Gerstein MB
,
Beltran H
et al.
. 2013.
Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression.
.
Cancer Res. 73(3):1232-44.
Li Y
,
Donmez N
,
Sahinalp C
,
Xie N
,
Wang Y
,
Xue H
,
Mo F
,
Beltran H
,
Gleave M
,
Wang Y
et al.
. 2017.
SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition.
.
Eur Urol. 71(1):68-78.
Lee DJ
,
Cha EK
,
Dubin JM
,
Beltran H
,
Chromecki TF
,
Fajkovic H
,
Scherr DS
,
Tagawa ST
,
Shariat SF
. 2012.
Novel therapeutics for the management of castration-resistant prostate cancer (CRPC).
.
BJU Int. 109(7):968-85.
Lapuk AV
,
Wu C
,
Wyatt AW
,
McPherson A
,
McConeghy BJ
,
Brahmbhatt S
,
Mo F
,
Zoubeidi A
,
Anderson S
,
Bell RH
et al.
. 2012.
From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer.
.
J Pathol. 227(3):286-97.
K
Ku SYu
,
Rosario S
,
Wang Y
,
Mu P
,
Seshadri M
,
Goodrich ZW
,
Goodrich MM
,
Labbé DP
,
Gomez ECortes
,
Wang J
et al.
. 2017.
Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance.
.
Science. 355(6320):78-83.
Klimstra DS
,
Beltran H
,
Lilenbaum R
,
Bergsland E
. 2015.
The spectrum of neuroendocrine tumors: histologic classification, unique features and areas of overlap.
.
Am Soc Clin Oncol Educ Book. :92-103.
G
Gillessen S
,
Omlin A
,
Attard G
,
de Bono JS
,
Efstathiou E
,
Fizazi K
,
Halabi S
,
Nelson PS
,
Sartor O
,
Smith MR
et al.
. 2016.
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.
.
Ann Oncol.
Gao D
,
Vela I
,
Sboner A
,
Iaquinta PJ
,
Karthaus WR
,
Gopalan A
,
Dowling C
,
Wanjala JN
,
Undvall EA
,
Arora VK
et al.
. 2014.
Organoid cultures derived from patients with advanced prostate cancer.
.
Cell. 159(1):176-87.
Galletti G
,
Matov A
,
Beltran H
,
Fontugne J
,
Mosquera JMiguel
,
Cheung C
,
MacDonald TY
,
Sung M
,
O'Toole S
,
Kench JG
et al.
. 2014.
ERG induces taxane resistance in castration-resistant prostate cancer.
.
Nat Commun. 5:5548.
F
Frampton GM
,
Fichtenholtz A
,
Otto GA
,
Wang K
,
Downing SR
,
He J
,
Schnall-Levin M
,
White J
,
Sanford EM
,
An P
et al.
. 2013.
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing.
.
Nat Biotechnol. 31(11):1023-31.
E
Epstein JI
,
Amin MB
,
Beltran H
,
Lotan TL
,
Mosquera J-M
,
Reuter VE
,
Robinson BD
,
Troncoso P
,
Rubin MA
. 2014.
Proposed morphologic classification of prostate cancer with neuroendocrine differentiation.
.
Am J Surg Pathol. 38(6):756-67.
D
Demichelis F
,
Setlur SR
,
Banerjee S
,
Chakravarty D
,
Chen JYun Helen
,
Chen CX
,
Huang J
,
Beltran H
,
Oldridge DA
,
Kitabayashi N
et al.
. 2012.
Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer risk.
.
Proc Natl Acad Sci U S A. 109(17):6686-91.
Davies AH
,
Beltran H
,
Zoubeidi A
. 2018.
Cellular plasticity and the neuroendocrine phenotype in prostate cancer.
.
Nat Rev Urol.
Dardenne E
,
Beltran H
,
Benelli M
,
Gayvert K
,
Berger A
,
Puca L
,
Cyrta J
,
Sboner A
,
Noorzad Z
,
MacDonald T
et al.
. 2016.
N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer.
.
Cancer Cell. 4(30):563-577.
C
Collins CC
,
Volik SV
,
Lapuk AV
,
Wang Y
,
Gout PW
,
Wu C
,
Xue H
,
Cheng H
,
Haegert A
,
Bell RH
et al.
. 2012.
Next generation sequencing of prostate cancer from a patient identifies a deficiency of methylthioadenosine phosphorylase, an exploitable tumor target.
.
Mol Cancer Ther. 11(3):775-83.
Choe H
,
Sboner A
,
Beltran H
,
Nanus D
,
Tagawa ST
. 2016.
PO-43 - Differential coagulation factor expression in neuroendocrine prostate cancer (PC), metastatic castrate-resistant PC, and localized prostatic adenocarcinoma.
.
Thromb Res. 140 Suppl 1:S192.
Chedgy ECp
,
Vandekerkhove G
,
Herberts C
,
Annala M
,
Donoghue AJ
,
Sigouros M
,
Ritch E
,
Struss W
,
Konomura S
,
Liew J
et al.
. 2018.
Biallelic tumor suppressor loss and DNA repair defects in de novo small cell prostate cancer.
.
J Pathol.
Chakravarty D
,
Sboner A
,
Nair SS
,
Giannopoulou E
,
Li R
,
Hennig S
,
Mosquera JMiguel
,
Pauwels J
,
Park K
,
Kossai M
et al.
. 2014.
The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer.
.
Nat Commun. 5:5383.
B
Bishop JL
,
Thaper D
,
Vahid S
,
Davies A
,
Ketola K
,
Kuruma H
,
Jama R
,
Nip KMun
,
Angeles A
,
Johnson F
et al.
. 2017.
The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer.
.
Cancer Discov. 7(1):54-71.
Beltran H
,
Wyatt AW
,
Chedgy E
,
Donoghue A
,
Annala M
,
Warner E
,
Beja K
,
Sigouros M
,
Mo F
,
Fazli L
et al.
. 2017.
Impact of therapy on genomics and transcriptomics in high-risk prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy.
.
Clin Cancer Res.
Beltran H
,
Rickman DS
,
Park K
,
Chae SS
,
Sboner A
,
MacDonald TY
,
Wang Y
,
Sheikh KL
,
Terry S
,
Tagawa ST
et al.
. 2011.
Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets.
.
Cancer Discovery. 1(6):487-95.
Beltran H
,
Tagawa ST
,
Park K
,
Macdonald T
,
Milowsky MI
,
Mosquera JMiguel
,
Rubin MA
,
Nanus DM
. 2012.
Challenges in recognizing treatment-related neuroendocrine prostate cancer.
.
J Clin Oncol. 30(36):e386-9.
Beltran H
. 2016.
Update on the biology and management of neuroendocrine prostate cancer.
.
Clin Adv Hematol Oncol. 14(7):513-5.
Beltran H
,
Beer TM
,
Carducci MA
,
de Bono J
,
Gleave M
,
Hussain M
,
Kelly WK
,
Saad F
,
Sternberg C
,
Tagawa ST
et al.
. 2011.
New therapies for castration-resistant prostate cancer: efficacy and safety.
.
Eur Urol. 60(2):279-90.
« first
‹ previous
1
2
(current)
3
next ›
last »